Clinical Trials Logo
  1. Home
  2. Other
  3. NCT03916185

Safety and Immunogenicity of a Single Dose of the Recombinant Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccines RSV ΔNS2/Δ1313/I1314L, RSV 6120/ΔNS2/1030s, RSV 276 or Placebo, Delivered as Nose Drops to RSV-Seronegative Children 6 to 24 Months of Age

Respiratory Syncytial Virus (RSV) Clinical Trial

Official title:
Randomized Phase I/II Study of the Safety and Immunogenicity of a Single Dose of the Recombinant Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccines RSV ΔNS2/Δ1313/I1314L, RSV 6120/ΔNS2/1030s, RSV 276 or Placebo, Delivered as Nose Drops to RSV-Seronegative Children 6 to 24 Months of Age

Clinical Trial Summary

The purpose of this study is to evaluate the safety and immunogenicity of a single dose of the recombinant live-attenuated respiratory syncytial virus (RSV) vaccines, RSV ΔNS2/Δ1313/I1314L, RSV 6120/ΔNS2/1030s, and RSV 276, in RSV-seronegative children 6 to 24 months of age.

Clinical Trial Description

This study will evaluate the safety and immunogenicity of a single dose of the recombinant live-attenuated respiratory syncytial virus (RSV) vaccines, RSV ΔNS2/Δ1313/I1314L, RSV 6120/ΔNS2/1030s, and RSV 276, in RSV-seronegative children 6 to 24 months of age. Participants will be randomly assigned to receive a single dose of RSV ΔNS2/Δ1313/I1314L vaccine, RSV 6120/ΔNS2/1030s vaccine, RSV 276 vaccine, or placebo intranasally at study entry. Participants will be enrolled in the study outside of RSV season. All participants will remain on study until they complete the post-RSV season visit between April 1 and April 30 in the calendar year following enrollment. Participants' total study duration will be between 6 and 13 months, depending on when they enroll in the study. Participants will attend several study visits throughout the study, which may include physical examinations, blood collection, and nasal washes. Participants' parents or guardians will be contacted by study staff at various times during the study to monitor participants' health. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03916185
Study type Interventional
Source National Institute of Allergy and Infectious Diseases (NIAID)
Contact
Status Completed
Phase Phase 1/Phase 2
Start date May 16, 2019
Completion date April 25, 2024
View Details
See also
  Status Clinical Trial Phase
Completed NCT02593071 - Safety and Immunogenicity of the RSV-F Vaccine in Older Adults Previously Treated With the Same Vaccine or Placebo in the Prior Year. Phase 2
Completed NCT02282982 - Observational Program to Assess Respiratory Syncytial Virus (RSV) Hospitalization Rate in Population of Children at High-risk of Serious RSV Illness Who Received Palivizumab Immunoprophylaxis N/A
Completed NCT02266628 - Placebo- Controlled Study to Evaluate the Safety and Immunogenicity of the RSV-F Vaccine in Elderly Adults Phase 2
Completed NCT01704365 - RSV-F Vaccine Dose Ranging Study in Young Women Phase 2
Completed NCT01709019 - RSV-F Vaccine and Influenza Vaccine Co-Administration Study in the Elderly Phase 1
Recruiting NCT06185647 - Evaluation in Practice of the Impact of NIrsevimab on EmeRgency Use for BRONCHIOlitis
Recruiting NCT04925310 - Infection With Respiratory Syncytial Virus in Infants
Completed NCT02968173 - A Study to Assess the Safety and Effectiveness of Palivizumab Administered to Children at High Risk of Severe Respiratory Syncytial Virus (RSV) Infection in the Russian Federation and the Republic of Belarus Phase 3
Active, not recruiting NCT06077149 - Immunogenicity of RSV Vaccines in Residents of Long-Term Care Facilities (LTCF) Phase 4
Completed NCT02608502 - A Study to Evaluate the Efficacy of an RSV F Vaccine in Older Adults Phase 3
Recruiting NCT05047549 - Community-based RSV Surveillance in Infant Mortality: Minimally Invasive Tissue Sampling Study in Karachi, Pakistan
Terminated NCT04225897 - A Study to Learn About the Effects of Sisunatovir in Infants With Respiratory Syncytial Virus Lower Respiratory Tract Infection. Phase 2
Recruiting NCT06216093 - Phase I, First-In Human Study to Evaluate Safety and Tolerability of EuRSV in Healthy Adults Aged Between 19 Years and 80 Years Phase 1
Not yet recruiting NCT06392451 - LIAISON NES Influenza (FLU) A/B, Respiratory Syncytial Virus (RSV), & Coronavirus Disease 2019 (COVID-19) in Symptomatic Patients in Australia N/A
Completed NCT04927793 - Absorption, Metabolism, and Excretion (AME) Study of [14C]EDP-938 in Healthy Male Subjects Phase 1
Active, not recruiting NCT05443607 - Transplacental Transmission of RSV (TTRSV)
Recruiting NCT04896853 - Treatment of Respiratory Complications Associated With COVID19,Influenza ,Metapneumovirus,RSV Infection Using ProTrans® Phase 1
Completed NCT05842967 - A Study to Assess the Safety, Tolerability, and Immunogenicity of RSVpreF in Adults at High Risk of Severe RSV Disease Phase 3
Recruiting NCT04909021 - Safety and Immunogenicity of an Intranasal Vaccine for Respiratory Syncytial Virus in Seronegative Children 6-36 Months Phase 1
Completed NCT05900154 - A Study to Learn About the Safety and Immune Activity of RSVpreF in Children 2 to <18 Years of Age Phase 1